{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:01:08Z","timestamp":1788966068292,"version":"build-2803163510"},"reference-count":21,"publisher":"Japanese Circulation Society","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2022,3,25]]},"DOI":"10.1253\/circj.cj-21-0430","type":"journal-article","created":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T22:08:27Z","timestamp":1631311707000},"page":"699-708","source":"Crossref","is-referenced-by-count":16,"title":["Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of OPC-61815, a Prodrug of Tolvaptan for Intravenous Administration, in Patients With Congestive Heart Failure\u3000\u2015 A Phase II, Multicenter, Double-Blind, Randomized, Active-Controlled Trial \u2015"],"prefix":"10.1253","volume":"86","author":[{"given":"Naoki","family":"Sato","sequence":"first","affiliation":[{"name":"Kawaguchi Cardiovascular and Respiratory Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Uno","sequence":"additional","affiliation":[{"name":"Clinical Development Headquarters, Otsuka Pharmaceutical Co., Ltd."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiko","family":"Yamasaki","sequence":"additional","affiliation":[{"name":"Clinical Development Headquarters, Otsuka Pharmaceutical Co., Ltd."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Hirano","sequence":"additional","affiliation":[{"name":"Medical Affairs, Otsuka Pharmaceutical Co., Ltd."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seongryul","family":"Kim","sequence":"additional","affiliation":[{"name":"Clinical Development Headquarters, Otsuka Pharmaceutical Co., Ltd."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the OPC-61815 Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Gheorghiade M, Follath F, Ponikowski P, Barsuk JH, Blair JE, Cleland JG, et al. Assessing and grading congestion in acute heart failure: A scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. <i>Eur J Heart Fail<\/i> 2010; 12: 423\u2013433.","DOI":"10.1093\/eurjhf\/hfq045"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. O\u2019Connor CM, Stough WG, Gallup DS, Hasselblad V, Gheorghiade M. Demographics, clinical characteristics, and outcomes of patients hospitalized for decompensated heart failure: Observations from the IMPACT-HF registry. <i>J Card Fail<\/i> 2005; 11: 200\u2013205.","DOI":"10.1016\/j.cardfail.2004.08.160"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Sato N, Kajimto K, Keida T, Mizuno M, Minami Y, Yumino D, et al. Clinical features and outcome in hospitalized heart failure in Japan (from the ATTEND registry). <i>Circ J<\/i> 2013; 77: 944\u2013951.","DOI":"10.1253\/circj.CJ-13-0187"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Boorsma EM, Ter Maaten JM, Damman K, Dinh W, Gustafsson F, Goldsmith S, et al. Congestion in heart failure: A contemporary look at physiology, diagnosis and treatment. <i>Nat Rev Cardiol<\/i> 2020; 17: 641\u2013655.","DOI":"10.1038\/s41569-020-0379-7"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Goldsmith SR, Bart BA, Burnett J. Decongestive therapy and renal function in acute heart failure: Time for a new approach? <i>Circ Heart Fail<\/i> 2014; 7: 531\u2013535.","DOI":"10.1161\/CIRCHEARTFAILURE.113.000828"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Tsutsui H, Isobe M, Ito H, Ito H, Okumura K, Ono M, et al. JCS 2017\/JHFS 2017 guideline on diagnosis and treatment of acute and chronic heart failure: Digest version. <i>Circ J<\/i> 2019; 83: 2084\u20132184.","DOI":"10.1253\/circj.CJ-19-0342"},{"key":"7","unstructured":"7. Yamamura Y, Nakamura S, Itoh S, Hirano T, Onogawa T, Yamashita T, et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: Pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. <i>J Pharmacol Exp Ther<\/i> 1998; 287: 860\u2013867."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Miyazaki T, Fujiki H, Yamamura Y, Nakamura S, Mori T. Tolvaptan, an orally active vasopressin V<sub>2<\/sub>-receptor antagonist: Pharmacology and clinical trials. <i>Cardiovasc Drug Rev<\/i> 2007; 25: 1\u201313.","DOI":"10.1111\/j.1527-3466.2007.00001.x"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Inomata T, Izumi T, Matsuzaki M, Hori M, Hirayama A. Phase III clinical pharmacology study of tolvaptan. <i>Cardiovasc Drugs Ther<\/i> 2011; 25(Suppl. 1): 57\u201365.","DOI":"10.1007\/s10557-011-6349-x"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Udelson JE, Bilsker M, Hauptman PJ, Sequeira R, Thomas I, O\u2019Brien T, et al. A multicenter, randomized, double-blind, placebo-controlled study of tolvaptan monotherapy compared to furosemide and the combination of tolvaptan and furosemide in patients with heart failure and systolic dysfunction. <i>J Card Fail<\/i> 2011; 17: 973\u2013981.","DOI":"10.1016\/j.cardfail.2011.08.005"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Matsue Y, Ter Maaten JM, Suzuki M, Torii S, Yamaguchi S, Fukamizu S, et al. Early treatment with tolvaptan improves diuretic response in acute heart failure with renal dysfunction. <i>Clin Res Cardiol<\/i> 2017; 106: 802\u2013812.","DOI":"10.1007\/s00392-017-1122-1"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Matsuzaki M, Hori M, Izumi T, Fukunami M; Tolvaptan Investigators. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: A phase III, randomized, double-blind, placebo-controlled study (QUEST study). <i>Cardiovasc Drugs Ther<\/i> 2011; 25(Suppl 1): S33\u2013S45.","DOI":"10.1007\/s10557-011-6304-x"},{"key":"13","unstructured":"13. Otsuka Pharmaceutical Co., Ltd. Jynarque: Highlights of prescribing information. 2020. https:\/\/www.otsuka-us.com\/media\/static\/JYNARQUE-PI.pdf (accessed August 31, 2021)."},{"key":"14","unstructured":"14. Otsuka Pharmaceutical Co., Ltd. Samsca: Highlights of prescribing information. 2019. https:\/\/www.otsuka-us.com\/media\/static\/Samsca-PI.pdf (accessed August 31, 2021)."},{"key":"15","unstructured":"15. Center for Drug Evaluation and Research. Jynarque: Clinical pharmacology review. 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/204441Orig1s000ClinPharmR.pdf (accessed August 31, 2021)."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Inomata T, Ikeda Y, Kida K, Shibagaki Y, Sato N, Kumagai Y, et al. Effects of additive tolvaptan vs. increased furosemide on heart failure with diuretic resistance and renal impairment: Results from the K-STAR study. <i>Circ J<\/i> 2017; 82: 159\u2013167.","DOI":"10.1253\/circj.CJ-17-0179"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Jujo K, Saito K, Ishida I, Furuki Y, Kim A, Suzuki Y, et al. Randomized pilot trial comparing tolvaptan with furosemide on renal and neurohumoral effects in acute heart failure. <i>ESC Heart Fail<\/i> 2016; 3: 177\u2013188.","DOI":"10.1002\/ehf2.12088"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Shoaf S, Wang Z, Bricmont P. Pharmacokinetics, pharmacodynamics, and safety of tolvaptan, a nonpeptide AVP antagonist, during ascending single-dose studies in healthy subjects. <i>J Clin Pharmacol<\/i> 2007; 47: 1498\u20131507.","DOI":"10.1177\/0091270007307877"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Kim S, Hasunuma T, Sato O. Pharmacokinetic, pharmacodynamic and safety of tolvaptan, a novel, oral, selective non-peptide AVP V2-receptor antagonist: Results of single- and multiple-dose studies in healthy Japanese male volunteers. <i>Cardiovasc Drugs Ther<\/i> 2011; 25(Suppl. 1): 5\u201317.","DOI":"10.1007\/s10557-011-6299-3"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Shoaf S, Kim S, Bricmont P. Pharmacokinetics and pharmacodynamics of single-dose oral tolvaptan in fasted and non-fasted states in healthy Caucasian and Japanese male subjects. <i>Eur J Clin Pharm<\/i> 2012; 68: 1595\u20131603.","DOI":"10.1007\/s00228-012-1295-5"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Shoaf S, Bricmont P, Mallikaarjun S. Absolute bioavailability of tolvaptan and determination of minimally effective concentrations in healthy subjects. <i>Int J Clin Pharmacol Ther<\/i> 2012; 50: 150\u2013156.","DOI":"10.5414\/CP201621"}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/86\/4\/86_CJ-21-0430\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,26]],"date-time":"2022-03-26T04:39:10Z","timestamp":1648269550000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/86\/4\/86_CJ-21-0430\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,25]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1253\/circj.cj-21-0430","relation":{},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"value":"1346-9843","type":"print"},{"value":"1347-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,25]]},"article-number":"CJ-21-0430"}}